Research Article

Insights into the pathological mechanisms of p85α mutations using a yeast-based phosphatidylinositol 3-kinase model

Maria D. Oliver¹,²,*, Teresa Fernández-Acero¹,*, Sandra Luna³, Isabel Rodríguez-Escudero¹, María Molina¹, Rafael Pulido²,³,⁴ and Víctor J. Cid¹

¹Dpto. de Microbiología II, Facultad de Farmacia, Universidad Complutense de Madrid and Instituto Ramón y Cajal de Investigaciones Sanitarias (IRyCIS), 28040 Madrid, Spain; ²Centro de Investigación Príncipe Felipe, 46012 Valencia, Spain; ³Biocruces Health Research Institute, 48903 Barakaldo, Spain; ⁴IKERBASQUE, Basque Foundation for Science, 48013 Bilbao, Spain

Correspondence: Rafael Pulido (rpulidomurillo@gmail.com, rafael.pulidomurillo@osakidetzak.eus) or Víctor J. Cid (viccid@ucm.es)

OPEN ACCESS

In higher eukaryotes, cell proliferation is regulated by class I phosphatidylinositol 3-kinase (PI3K), which transduces stimuli received from neighboring receptors by local generation of PtdIns(3,4,5)P³ in cellular membranes. PI3K is a heterodimeric protein consisting of a regulatory and a catalytic subunit (p85 and p110 respectively). Heterologous expression of p110α in Saccharomyces cerevisiae leads to toxicity by conversion of essential PtdIns(4,5)P² into futile PtdIns(3,4,5)P³, providing a humanized yeast model for functional studies on this pathway. Here, we report expression and functional characterization in yeast of all regulatory and catalytic human PI3K isoforms, and exploitation of the most suitable setting to functionally assay panels of tumor- and germ line-associated PI3K mutations, with indications to the limits of the system. The activity of p110α in yeast was not compromised by truncation of its N-terminal adaptor-binding domain (ABD) or inactivation of the Ras-binding domain (RBD). In contrast, a cluster of positively charged residues at the C2 domain was essential.

Introduction

Synthesis of PtdIns(3,4,5)P³ by phosphatidylinositol 3-kinase (PI3K) physiologically occurs in cellular membranes in response to the stimulation of growth factor receptors and other stimuli. PtdIns(3,4,5)P³-responsive downstream effectors of PI3K include, sequentially, phosphoryositide-dependent kinase (PDK), Akt, and mTOR protein kinases, involved in multiple functions related to transcriptional regulation and protein synthesis [1-3]. Activation of these pathways ultimately promotes cell proliferation and growth, cell motility, and inhibition of programmed cell death [4]. Deregulation and hyperactivation of PI3K signaling is a landmark of multiple pathologies, especially cancer. The most common mutations leading to enhanced PtdIns(3,4,5)P³-dependent signaling map in the phosphatase and tensin homolog deleted on chromosome ten (PTEN) phosphoinositide
3-phosphatase, a prominent tumor suppressor [5-8]. Somatic gain-of-function mutations in the coding region of both PI3K subunit genes, \(PIK3R1\) (coding for p85\(\alpha\), the regulatory subunit of isoform \(\alpha\) class I PI3K heterodimer) and \(PIK3CA\) (encoding the p110\(\alpha\) catalytic subunit), are commonly found in many tumor types [9-12]. Such point mutations often appear in hotspots that correspond to structural regions that account for fine allosteric regulation of p110 by p85, such as those involved in the inhibitory interaction between the SH2 domains of p85 and p110 (reviewed in [13]). Archetypal examples of such oncogenic mutations are (i) the truncated p65\(\alpha\) version of p85\(\alpha\), isolated from a murine lymphoma [14], which lacks the C-terminal SH2 (cSH2) domain, thus presumably affecting the inhibitory function mediated by the preceding N-terminal and intermediate SH2 domains (nSH2 and iSH2); or (ii) the p110\(\alpha\) E545K point mutant in the helical domain [15], which relieves such inhibitory interaction [16]. Although crystallographic studies have revealed the interaction surfaces of the p85–p110 complex, many mechanistic questions about the regulation imposed on p110 by p85 remain unsolved.

The application of the latest analytical technologies to cancer genomics, such as single cell whole exome sequencing performed on tumors by The Cancer Genome Atlas (TCGA) project and others, is revealing a plethora of mutations in these oncogenic pathways [17-19]. Addressing whether such mutations have an influence in the function of these oncoproteins and by which molecular mechanisms they operate is currently an important scientific challenge. Saccharomyces cerevisiae is an easily manipulatable and genetically tractable model organism for molecular studies on heterologously expressed proteins. We have previously developed a ‘humanized yeast’ model by heterologous expression of the mammalian PI3K catalytic subunit (p110\(\alpha\)) artificially driven to yeast membranes by a C-terminal prenylation box [20], and thoroughly exploited it for functional analyses of mutations in the tumor suppressor PTEN [21-25]. The model relies on the fact that budding yeast lacks PtdIns(3,4,5)P\(_3\)-dependent pathways, but expression of the mammalian class I PI3K severely depletes its substrate PtdIns(4,5)P\(_2\) from the plasma membrane. The latter phosphoinositide is essential for polarized secretion and endocytosis in yeast, so its elimination by in vivo PI3K activity is reflected as growth inhibition [20,24].

Here, we explore the applicability of this yeast setting to perform functional studies on PI3K by co-expression of its regulatory and catalytic subunits. We used a set of mutants to evaluate the aspects and define the limits of PI3K regulation that can be assayed in this heterologous model. We found that the key features related to oncogenesis, namely PI3K gain-of-function by p85-dependent recruitment to the plasma membrane, and disruption of inhibitory p85–p110 interactions can be traced in yeast. Moreover, p85\(\alpha\) mutations associated with the non-oncological short stature, hyperextensibility of joints and/or inguinal hernia, ocular depression, Rieger anomaly, and teething delay (SHORT) syndrome [26-28] behaved differently in our model as compared with those purportedly oncogenic, suggesting distinct pathological mechanisms for tumor- and germ line-associated p85\(\alpha\) mutations.

**Results**

**Involvement of distinct p110\(\alpha\) domains in intrinsic PI3K activity in the heterologous yeast model**

In previous studies, we developed a humanized yeast system by heterologously expressing p110, Akt, and PTEN isoforms [20,24,29]. Within that frame, we described that, when overproduced from the strong GAL1 promoter (induced in galactose as a carbon source), p110\(\alpha\) and \(\beta\) isoforms led to severe and mild, respectively, growth inhibition in yeast. This required their expression as membrane-directed proteins by attachment of an H–Ras C-terminal prenylation box (p110\(\alpha\)–CAAX and p110\(\beta\)–CAAX), and was dependent on p110 catalytic activity (Figure 1) [20,21]. Although p110\(\alpha\) did not inhibit yeast growth by itself in the absence of this membrane attachment signal, co-expression of native p110\(\alpha\) and Akt isoforms led to growth inhibition by a different mechanism that relied on the activity of the Akt kinase [29]. However, the oncogenic mutation H1047R of p110\(\alpha\) did show an evident degree of inhibition, thus reproducing its intrinsic hypermorphic phenotype [21]. In order to gain insight on the significance of both the C2 and Ras-binding domain (RBD) domains on p110\(\alpha\) kinase activity by using the yeast model, we generated point mutations that potentially inactivate such domains in all three p110\(\alpha\)–CAAX, p110\(\alpha\)–H1047R, and p110\(\alpha\) + Akt1 yeast experimental settings.

C2 domains bear structural motifs related to interaction with membrane phospholipids. It has been suggested that a cluster of positive residues in the p110\(\alpha\) C2 domain (K410, R412, K413, and K416) was involved in its interaction with the plasma membrane through electrostatic interactions [30]. Therefore, we simultaneously mutated these four residues to alanine to locally reduce such positive charges. The resulting p110\(\alpha\)–(K410A, R412A, K413A, K416A) will be referred hereafter as p110\(\alpha\)–C2/4KA. As shown in Figure 1A, p110\(\alpha\)–C2/4KA–CAAX kept its ability to strongly inhibit yeast growth, indicating that kinase activity was not impaired by the quadruple C2 mutation. However, p110\(\alpha\)–C2/4KA fully lost its ability to activate Akt in yeast in the absence of a membrane-targeting prenylation
whether these (AB mutations tested in (A)–(C) panels.

Figure 1. Contribution of C2 and RBD domains to p110α activity in yeast

(A) 10-fold serial dilutions of wild-type YPH499 yeast transformed with empty YCpLG (vector) as growth control for plasmids, YCpLG–p110α–CAAX, YCpLG–p110α (K802R)–CAAX, YCpLG–p110α (C2/4KA)–CAAX, and YCpLG–p110α (K227E)–CAAX, as indicated. (B) Growth assay of cells co-transformed with YCpLG and pYES2 (vectors) or pYES2–GFP–Akt1 with YCpLG–p110α, pYES2–GFP–Akt1 (K179M; kinase-dead) with YCpLG–p110α, and pYES2–GFP–Akt1 with YCpLG–p110α (C2/4KA) or with YCpLG–p110α (K227E), as indicated. (C) Drop agar growth assay on yeast transformed with YCpLG–p110α (H1047R), YCpLG–p110α (C2/4KA–H1047R), and YCpLG–p110α (K227E–H1047R), as indicated. Yeast cells suspensions were spotted on synthetic complete (SC) medium, lacking the appropriate auxotrophic selection plasmid markers with either glucose (repression conditions) or galactose (for GAL1-driven expression) as carbon sources, respectively, as indicated. A representative experiment is shown from triplicate transformant clones assayed. Plates were incubated for 48 (glucose) or 72 h (galactose) at 28°C. A p110α primary structure sketch on top is provided as a reference to locate the mutations tested in (A)–(C) panels.

CAAX signal (Figure 1B), proving that membrane recognition by the C2 domain is essential for p110α performance. Moreover, the C2/4KA mutations suppressed hyperactivation by the H1047R mutation (Figure 1C), denoting that the function of the C2 domain contributes to the enhanced activity of this allele.

In mammalian cells, interaction of p110 with the Ras oncoprotein via its RBD domain reinforces its recruitment to the plasma membrane thus contributing to PI3K activation [31]. Yeast possesses two Ras homologs, Ras1 and Ras2 [32], which could be playing this role in activation of heterologous p110. To test whether RBD function was determinant for p110α activity in yeast, we introduced the K227E mutation, which abolishes the interaction with Ras in mammalian cells [33], in the same expression settings as above. In all cases, the K227E mutant behaved as the equivalent p110α version with a wt RBD (Figure 1A–C). These results imply that RBD function is not necessary for inherent p110α kinase activity in vivo.

The interaction between the regulatory subunit p85 iSH2 domain and the N-terminal adaptor-binding domain (ABD) of p110 facilitates interaction with the plasma membrane [16], triggering the signaling cascade. In yeast, membrane-targeted p110 is active in the absence of p85, so we could address, by generating N-terminal truncations, whether these domains were structurally necessary for intrinsic p110 PI3K activity in vivo. Hence, we generated a series of N-terminal-truncated versions of both p110α and β isoforms, as shown in Figure 2. For p110α we generated truncations lacking the ABD domain (p110α Δ1-107), the ABD domain and a fragment of the ABD/RBD linker (p110α Δ1-154), and the ABD domain plus the whole ABD/RBD linker (p110α Δ1-186). For p110β we generated truncations lacking the ABD domain (p110β Δ1-117) and the ABD domain plus the whole linker ABD/RBD (p110β Δ1-190). In both cases, truncations were produced both in the absence and in the presence of a C-terminal
prenylation signal. Plasma membrane-directed constructions lacking the ABD domain (p110α Δ1-107–CAAX and p110β Δ1-117–CAAX) still caused yeast growth inhibition (Figure 2), whereas those lacking ABD domain and the whole linker (p110α (Δ1-186) and p110β (Δ1-190)) had lost their activity. Moreover, partial loss of the linker was sufficient to cause activity loss in p110α (p110α (Δ1-154)–CAAX). A p110α Δ1-108 deletion displayed decreased expression in mammalian cells [34], suggesting that larger N-terminal truncations could have compromised stability. In line with this, we could not detect expression of our N-terminal p110 truncations in yeast. Thus, the whole ABD is dispensable, but additional N-terminal deletions in p110 yield it inactive in yeast, likely by protein destabilization.

Expression and function of PI3K regulatory subunits in yeast

To reconstruct in yeast a mammalian PI3K activity and regulation, we extended our system by expressing PI3K regulatory subunits. For this purpose, we expressed HA-tagged versions of the p85α and β isoforms, in addition to a p65α oncogenic C-terminal truncation comprising amino acids 1–571 [14], its corresponding truncation in p85β, hereafter referred as p65β (comprising residues 1–568) as well as p55α, p50α, p55γ, and p101. Although the proteins were properly overproduced under galactose induction conditions, as determined by immunoblot with anti-HA antibodies, they did not interfere with yeast growth or led to obvious phenotypes, neither when expressed alone (results not shown) or in combination with p110α, β, δ, and γ isoforms (Figure 3A). None of the regulatory subunits did counteract the strong inhibitory activity of p110α–CAAX. However, when co-expressed with p110β–CAAX, both p65α and p65β C-terminal truncations enhanced its toxicity (Figure 3A), suggesting that they exerted an activating effect on p110β, in agreement with the reported oncogenic activity of p65α [14].
Figure 3. Effects of co-expression of p85 and p110 subunits and myristoylation of p110α

(A) Expression of all class I PI3K regulatory subunits in yeast in combination with native or C-terminally prenylatable p110 subunits. Color-code graphical representation of the effect on yeast growth in galactose, assayed as in Figures 1 and 2, of the co-transformants bearing either empty pYES3/CT vector (ϕ) or plasmids bearing the regulatory subunits pYES3–p85α, pYES3–p65α, pYES3–p65β, pYES3–p65γ, pYES3–p55α, pYES3–p50α, pYES3–p55γ, and pYES3–p101, in combination with plasmids YCpLG–p110α, YCpLG–p110β, YCpLG–p110γ, YCpLG–p110α–CAAX, YCpLG–p110β–CAAX, YCpLG–p110γ–CAAX, and YCpLG–p110γ–CAAX as indicated. Green color indicates wild-type-like growth and yellow, orange, and red colors indicate different degrees of growth inhibition, as indicated in the legend. Below the grid, a representative experiment is shown, corresponding to the YCpLG–p110β or YCpLG–p110γ–CAAX transformants combined with pYES3 (vector), pYES3–p65α, or pYES3–p65γ. (B) Activation of p110α by myristoylation. Growth assay of serial dilutions of YCpLG–FLAG–p110α, YCpLG–Myr–p110α, and YCpLG–MM–p110α transformants, as indicated. On the left side, the amino acidic sequences of the corresponding extra N-terminal extensions are shown. (C) Inhibition of Myr–p110α by p85α. Growth assay on co-transformants bearing YCpLG–p110α, YCpLG–p110α–CAAX, or YCpLG–Myr–p110α in combination with empty pYES3/CT (vector), pYES3–p85α, or pYES3–p65α. (D) Modulation of p110 versions by C-terminal prenylation of wild-type and truncated p85α. Growth assay on transformants bearing the pYES3/CT empty plasmid (ϕ or vector) or pYES3–p85α–CAAX, pYES3–p65α–CAAX co-existing with plasmids YCpLG–p110α, YCpLG–p110α–CAAX, YCpLG–p110β–CAAX, YCpLG–p110γ–CAAX, YCpLG–p110γ–CAAX, and YCpLG–Myr–p110α, as indicated. Both a color-code grid (left; same code as in Figure 3A) and an equivalent representative experiment (right) are shown. All experiments were performed in the YPH499 yeast strain, following the same procedures as in Figures 1 and 2. On the left side of each panel, a graphical representation of the corresponding combinations assayed is shown. C-terminal prenylation is depicted by a Cys bridge (C); N-terminal myristoylation is marked as a Gly bridge (G).
Unlike higher cells, *S. cerevisiae* lacks tyrosine phosphorylation as a prominent signaling event. Thus, it was expected that activation of p110 by p85-dependent recruitment was not naturally reproduced in yeast, imposing some limits to our analysis. Still, these results underscore the requirement of the recruitment of p110α and p110β to plasma membrane for its function. Since C-terminal prenylation is probably too strong as a membrane-directing signal for p110α to actually detect fine-tuning interactions with p85, we tested N-terminal myristoylation as an alternative p110α membrane-targeting strategy. As shown in Figure 3B and 3C, Myr–p110α caused a moderate but significant inhibition of yeast growth as compared with p110α–CAAX. This was not due to sheer modification of p110α N-terminal end [35], as the expression of a mutant in which the glycine subjected to myristoylation was mutated to Ala (MM–p110α), was innocuous, as was a FLAG-tagged p110α version (FLAG–p110) (Figure 3B). The observation that Myr–p110α expression led to an intermediate growth inhibition phenotype, as compared with those of p110α–CAAX and p110α, prompted us to evaluate the effect of p85α/p65α in these conditions. Interestingly, p85α down-regulated Myr–p110α activity in yeast (Figure 3C), suggesting that the inhibitory effect performed by the regulatory subunits in the absence of tyrosine-phosphorylated receptors could be reproduced in the yeast system. In contrast, we were not able to reproduce on Myr–p110α the positive regulation carried out by the oncogenic version p65α on p110β–CAAX.

Finally, we introduced a CAAX prenylation signal on p85α and p65α, thus mimicking their membrane attachment by activated receptor tyrosine kinases (RTKs) in higher cells. We evaluated their effects on both plasma membrane-anchored p110 isoforms (p110α–CAAX, Myr–p110α, p110β–CAAX, p110δ–CAAX, and p110γ–CAAX) and their corresponding soluble forms (p110α, p110β, p110δ, and p110γ). Remarkably, p65α–CAAX enhanced the activity of all the class IA catalytic subunits tested (p110α, p110β, p110β–CAAX, p110δ, and p110γ–CAAX) but not that of class IB (p110γ) (Figure 3D). In contrast, like non-prenylated p85, p85α–CAAX down-regulated Myr–p110α activity in yeast, and slightly reduced p110β–CAAX toxicity (Figure 3D). Together, our findings illustrate that the yeast system can be used to investigate diverse aspects of PI3K function, related to membrane targeting, enzyme allosteric regulation, and perhaps stabilization, which affect differentially to the distinct PI3K class IA catalytic subunits.

**Functional studies on p85α−dependent regulation of p110 in yeast**

The above data show that the p65α–CAAX + p110α combination could be an appropriate setting to reproduce the positive effect of membrane recruitment of p110 by p85 in the absence of the inhibitory interaction imposed by full-length p85. Toxicity in yeast of the p65α–CAAX/p110α pair was dependent on its catalytic PI3K activity since (i) growth inhibition was counteracted by co-expression of PTEN (Figure 4A); (ii) it could be reverted by a p110 chemical inhibitor (Figure 4B); and (iii) a kinase-dead mutant p110α (K802R) was innocuous (Figure 4C). Moreover, the p65–CAAX/p110α combination was competent in activating co-expressed Akt1 leading to growth arrest, which could also be counteracted by a PI3K inhibiting compound (Figure 4B).

We then combined p65α–CAAX with mutants in different p110α domains. Co-expression with the p110α Δ1–107–truncated mutant showed that p65α–CAAX requires the presence of the p110α ABD domain to exert activating interaction (Figure 4C). Also, p110α–C2/4KA failed to become activated by p65α–CAAX, indicating that the ability of p110α itself to interact with the plasma membrane was determinant for an effective p65α–induced recruitment and activation (Figure 4C). In contrast, p65α–CAAX was fully competent activating the RBD-targeting p110α K227E mutation (Figure 4C).

Next, we used the p85α–CAAX to verify whether the negative regulation exerted by p85 on p110 in yeast involved inhibitory interaction between these two proteins. Indeed, the introduction of the oncogenic mutation E545K at the helical domain of p110α, which inverts the charge involved in electrostatic interactions with the nSH2 domain of p85α [36], released p110α from p85α–CAAX negative regulation: first, p85α–CAAX had an activating effect, compared with that of p65α–CAAX, on the p110α E545K mutant, but not on wild-type p110α (Figure 4D); and second, p85α–CAAX lost the ability to negatively regulate Myr–p110α when the E545K mutation was introduced in the latter (Figure 4D). Moreover, as described in higher cells [36], the introduction of a K379E mutation on the p85α nSH2 domain providing a complementary charge to that of p110α E545K was able to restore the inhibitory interaction. Thus, the combination of p85α K379E–CAAX with Myr–p110α E545K rescued yeast growth (Figure 4E). In conclusion, although our experiments do not directly measure protein–protein interactions, our results with the distinct combinations of mutations suggest that the yeast system recapitulates the p85–p110 allosteric regulatory interactions.

Finally, we tested whether the p110α H1047R mutant was sensitive to regulation by membrane-driven p85α. Interestingly, both p65α–CAAX and p85α–CAAX enhanced the activity of p110α H1047R (Figure 4D), suggesting...
Figure 4. Characterization of p85–p110 functional interactions in yeast

(A) Activation of p110 by p65 is counteracted by catalytically active PTEN. Growth of YPH499 triple transformants bearing pYES3–p65α–CAAX, YCpLG–p110α, and either pYES2 (vector), pYES2–PTEN, expressing the active phosphatase or pYES2–PTEN (C124S), expressing a phosphatase-dead PTEN mutant. (B) Halo growth assay on SC-galactose agar around a 6 mm-disk imbedded with PI3K inhibitor 15e. A representative assay is shown on agar spread with Y03951 (snq2Δ1-107) triple transformants bearing pYES2, pYES3/CT, and YCpLG (vectors, top left); pYES2, pYES3/CT, and YCpLG–p110α–CAAX (p110α–CAAX, top right); pYES2, pYES3–p65α–CAAX, and YCpLG–p110α (p65α–CAAX/p110α, bottom left); and pYES3–p65α–CAAX, YCpLG–p110α, and pYES2–GFP–Akt1 (p65α–CAAX/p110α/Akt1, bottom right). (C) The ABD and C2 domains are required for p110 activation by p65. Agar growth assays of YPH499 yeast co-transformed with either the pYES3 plasmid (vector) or pYES3–p65α–CAAX and the YCpLG empty plasmid (vector), YCpLG–p110α, YCpLG–p110α (K802R), YCpLG–p110α (Δ1-107), YCpLG–p110α (K227E), or YCpLG–p110α (C2/4KA), as indicated. (D) Mutants affecting the allosteric regulation of p110 by p65 in function. Growth assays of YPH499 co-transformed with the pYES3 plasmid (vector), pYES3–p85α–CAAX or pYES3–p65α–CAAX, in combination with YCpLG–p110α, YCpLG–p110α (E545K), YCpLG–Myr–p110α, YCpLG–Myr–p110α (E545K), and YCpLG–p110α (H1047R), as indicated. (E) Recovery of the inhibitory effect exerted by p85 on p110 by charge inversion in the nSH2/helical interface. Growth assay on a co-transformant bearing plasmids pYES3–p85α (K379E)–CAAX and YCpLG–p110α (E545K).

that the conformation of this allele is sensitive in yeast to p85-driven membrane recruitment but insensitive to its inhibitory inputs.

Enquiring cancer-related p85α mutations for function in the yeast system

The results above are suggestive that p85–p110 functional interactions can be traced in the yeast heterologous system. Thus, we chose a set of PIK3R1 (encoding p85α) mutations to be expressed as p85α–CAAX, including N564D and a series of selected p85α point mutations isolated in tumors, some previously assayed in vitro or in vivo in mammalian
cells, but most of them with a yet unclear mechanism [9,12,36–38]. We tested these mutants against both p110α and Myr–p110α. According to their behavior on the yeast system (Figure 5A and D), we were able to define three groups of mutations: (i) mutations that behave as the wild-type p85α–CAAX control, i.e. they exert a detectable inhibitory effect on Myr–p110α but do not have any effect on p110α (D13V, N260S, M326I, ΔK459, R574T, and E666K); (ii) a second group, conformed by K379E at the nSH2 domain and N564D at the iSH2 domain, behaved like p65α–CAAX, i.e. activating p110α and failing to inhibit Myr–p110α; and (iii) finally, mutations G376R (at nSH2) and D560Y (at iSH2) activated p110α but were able to inhibit Myr–p110α. The different performance of these sets of mutants was not biased by expression or stability in yeast since they were equivalently produced, as verified by Western blotting (Figure 5C).

**Germ line SHORT syndrome-related p85α mutations are competent for the inhibition of p110α**

Next, we tested a panel of germ line PIK3R1 mutations linked to the genetically inherited SHORT syndrome [39]. The panel covered most of the SHORT syndrome-associated PIK3R1 coding region mutations currently identified, as well as PIK3R1 mutations associated with colorectal cancer risk and with insulin resistance (HGMD® Human Gene Mutation Database) (Figure 5B and D). All these mutations behaved indistinguishably from wild-type p85α for their ability to modulate p110α in yeast (Figure 5B and D), suggesting that functional p85α–p110α interactions were intact. Noticeably, most of the SHORT syndrome-linked mutations targeted a cSH2 residue or introduced a stop codon at the cSH2 domain, suggesting a dispensable role for the p85α cSH2 domain in the direct control of p110α activity. In accordance, a W624* truncation lacking the entire p85α cSH2 domain was also indistinguishable from wild-type p85α (Figure 5B and D). The different SHORT-related mutations were properly expressed in yeast, as verified by immunoblot (Figure 5C). Overall, we conclude that the functional pattern of SHORT syndrome-associated p85α mutations differs from the p110α-activating pattern manifested by either p65α or the most prevalent tumor-associated p85α human mutations.

**Discussion**

In physiological conditions in higher eukaryotic cells, receptors activated by tyrosine phosphorylation recruit the p85–p110 PI3K heterodimer to the plasma membrane. The interaction between YXXM domains in receptor/adaptor proteins and p85 SH2 domains releases inhibitory interactions between such domains and the C2/helical domains in the p110 catalytic subunit. This allosteric regulation allows a conformational switch in the PI3K heterodimer, leading to full activation of the kinase in the proximity of its phosphoinositide substrate [16,36,40,41]. Hypermorphic mutations in PIK3CA and PIK3R1 genes, coding for the p110α and p85α proteins, are prevalent in numerous tumor types as verified by deep sequencing analyses in the frame of projects such as TCGA [17–19]. Hotspots for PI3K gain-of-function mutations are found at the interface between the SH2 domains of p85 and the C2/helical structures in p110, thus leading to constitutive PI3K activation by releasing the inhibitory interactions between both subunits [13,40,42,43].

Here, we show that the key mechanism events involved in pathologic PI3K hyperactivation, i.e. p85-driven plasma membrane recruitment and disruption of p85-imposed inhibition of p110, can be reproduced and traced in yeast. The key feature of reproducing in *S. cerevisiae* crucial aspects of PI3K regulation is that it provides an environment free of all the complex layers of regulation present in higher cells, but yet in an *in vivo* context. Thus, it permits studies of structure–function relationship properties inherent to the expressed proteins in the absence of additional inputs. However, limits to the use of the yeast system include the apparent lack of sensitivity to interaction with Ras, as well as its dependence on protein production and stabilization. When assaying catalytic p110 subunits in yeast in this and previous studies [20,21], we found that membrane targeting was essential for performance, by introduction of either an N-myristoylation or a C-terminal prenylation signal in the protein. The latter strategy was more effective, at least on p110α. We show here that a cluster of positively charged residues at the C2 domain (mutation C2/4KA) yields p110 inactive, but the effect of this multiple mutation can be by-passed by C-terminal prenylation. This confirms that the key function of the C2 domain is to facilitate contact with the negatively charged plasma membrane, as previously suggested [16,30]. However, prenylation of the regulatory subunit failed to activate the C2/4KA p110 mutant, indicating that these residues might also contribute to p85-dependent recruitment.

Among all class I PI3K catalytic isoforms individually tested, the p110α isoform appeared more active than the p110β isoform in terms of yeast growth inhibition, while p110γ and p110δ did not interfere with yeast growth when expressed alone. This could be related to a lower basal activity of the latter isoforms, as well as to a more limited ability to efficiently attach to membranes in the absence of the regulatory subunit, because when the oncogenic p85
Figure 5. Functional analyses of p85α pathologic mutants in yeast

Representative agar drop growth assays of selected YPH499 yeast transformant clones (A and B) and a graphical color-code display (D) of growth inhibition assays on all mutations tested by co-expression of the indicated combinations of plasmids: pYES3/CT (vector) or pYES3–p85α–CAAX (wt or bearing the indicated mutations or truncations) with YCpLG–p110α and YCpLG–Myr–p110α. (A) Selection of growth assays for clones expressing p85α mutations related to cancer. (B) Selection of growth assays for clones expressing p85α mutations related to SHORT disease, as well as a W624* truncation. N564D and p65α are shown as gain-of-function controls, as a reference. (C) Immunoblots showing the expression in yeast lysates of p85α mutants related to cancer or SHORT syndrome disease, as indicated. Membranes were hybridized with monoclonal anti-HA antibodies to detect N-terminally-tagged p85α variants and anti-G6PDH antibodies as a loading control. (D) A sketch of p85α primary structures and domains is shown (left). Blue, red, dark green, purple, and brown colors are used to depict localization of mutations to the different p85α domains. The pathology column relates mutations to the tumor type in which they were found (COSMIC database, http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/) [52] or their linkage to SHORT syndrome [26-28]; BC, breast carcinoma; BTC, biliary tract carcinoma; CRC, colorectal carcinoma; EC, endometrium carcinoma; PC, prostate carcinoma; SC, stomach carcinoma; UADTC, upper aerodigestive tract carcinoma; UTC, urinary tract carcinoma; fs frame shift. Italics indicate germ line mutation.
truncation p65α–CAAX was co-expressed, all compatible class IA catalytic subunits (p110α, β, and δ) were equally and strongly activated.

By assaying p110 N-terminal truncations, we found that removal of the whole ABD domain does not eliminate intrinsic p110α and p110β PI3K activity, as long as the enzymes were artificially directed to the membrane. However, as expected, the ABD was necessary for p85-dependent activation, as p110α Δ1-107 did not respond to activation by p65α–CAAX. Nevertheless, these experiments are hampered by the difficulty in detecting by immunoblot the p110 N-terminal truncations, probably by compromised stabilization.

The artificial introduction of a C-terminal prenylation CAAX box in PI3K regulatory subunits mimicked in yeast its recruitment by tyrosine-phosphorylated RTKs in mammalian cells, causing an up-regulation of p110 activity by p65α–CAAX, or its down-regulation in the case of p85α–CAAX on membrane-driven Myr–p110α or p110β–CAAX. These results favor the notion that the regulatory interplay between p85 and p110 subunits can be achieved in yeast. Accordingly, mutations affecting the negatively charged p110α loop spanning residues 541–546, which interact with the positively charged p85 nSH2 domain [44], such as the clinically relevant E545K tested here, yielded Myr–p110α active even in the presence of p85α–CAAX. As reported by Miled et al. [36], the introduction of a K379E charge inversion mutant at the nSH2 domain in p85 reestablished the inhibitory interaction, thus suppressing gain-of-function of the p110α E545K mutant. The fact that this fine regulation can be reproduced in yeast illustrates that the heterologous model is instrumental, and that this particular regulatory event takes place in the absence of the multiple factors that regulate PI3K activity in higher cells.

Interesting mechanistic observations can also be inferred from the yeast model about performance of the most common p110α missense point mutation in clinical oncology, namely H1047R, mapping at the kinase domain [15,42]. First, the fact that it is the only p110 tested that is able to inhibit yeast growth by itself in the absence of membrane-targeting signals [21] favors the hypothesis that this mutation adopts a conformation that facilitates membrane recognition [45]. In this regard, the observation that the loss of positive charges at the C2 domain in this mutant suppresses the hypermorphic trait of the H1047R mutation in the combined p110α–C2/4KA–H1047R mutant reveals that its hyperactive conformation depends on a functional C2 domain. Furthermore, p110α H1047R activity in yeast was enhanced by both p65α–CAAX and p85α–CAAX, suggesting that it adopts a conformation that fails to respond to p85-imposed inhibitory interactions, but still responds to p85-driven membrane recruitment, in agreement with previous reports on the transformation activity of combined PI3K mutations in higher cells [46]. It has been shown that p-tyrosine peptides activate the p110α H1047R mutant, probably by disrupting p85-mediated inhibition and/or by increasing p110α lipid binding [45,47]. Although we cannot exclude the possibility that the yeast system is not sensitive to detect inhibition of p110α H1047R by p85α, our results suggest an essential contribution of membrane binding to the hyperactivity of p110α H1047R in cells, as previously suggested by structural analyses [44,48].

To validate the usefulness of our system on assessing the mechanism of putative pathogenic mutations in p85α, we chose a series of mutants described in the clinics. Among the mutations linked to cancer, two of them reproduced unequivocally the behavior pattern of p65, suggesting that they fully disrupted n/ISH2–helical/C2 inhibitory interactions. These were K379E, which introduce a negative charge at a key residue of the nSH2 domain [43,49], as discussed above and interestingly, N564D at iSH2. The latter point mutation, one of the most frequent PIK3R1 found in tumors, is thought to disrupt the inhibitory interaction of the iSH2 domain in p85 with the C2 domain in p110 [12,30,45]. These results underscore the key involvement of the nSH2–helical and iSH2–C2 interactions in PI3K regulation. Interestingly, clinical mutations in nearby residues within the same hotspots, namely G376R (nSH2) and D560Y (iSH2) showed a different behavior: they maintained the ability to down-regulate membrane-targeted Myr–p110α, but they did activate soluble p110α. This might reflect a less potent gain-of-function activity than the previous class of mutations so that it can only be detected when p110 is not attached to the membrane by other means. In agreement with this view, G376R was less aggressive than K379E, and D560Y also seemed less potent as compared with N564D, regarding their ability to induce cell proliferation in higher cells, as tested by Sun et al. [43] and Jaiswal et al. [12] respectively. Other clinical mutations tested, ΔK459, predicted to disrupt the iSH2 α–helical fold [9,43] or R574T [12] did not behave differently than wild-type p85α in our system, which suggest that they may exert even a milder effect or, alternatively, that other cellular factors absent in yeast are involved in their oncogenic activity. This could be the case of the E666K mutation, mapping at the cSH2 domain, which is not presumably involved in p110 inhibition, as well as mutants in the SH3 (D13V) and GAP (N260S) domains of p85α that are assumed to contribute to pathology by mechanisms different than modulation of p110 activity. In line with this, germ line SHORT syndrome-related mutations in PIK3R1, which preferably target the cSH2 p85α domain, displayed in our yeast system an ability to modulate p110α indistinguishable from that of the wild-type p85α protein, even when large C-terminal
truncations eliminating most of the cSH2 were assayed. This supports the idea that these mutations may cause pathology by different molecular mechanisms than those involved in cancer. The mutation R649W, the most common p85α variant associated with SHORT syndrome, causes impaired PI3K signaling, probably by defective association with tyrosine-phosphorylated protein effectors, such as IRS-1 [26,28,50]. Our results suggest that, unlike oncogenic gain-of-function mutants, p85α mutations associated with SHORT syndrome do not affect the inhibitory interaction between p85α regulatory and p110α catalytic subunits, but rather the interactions of the cSH2 p85α domain with other proteins, which are absent in our humanized yeast model. This provides a rationale for further scrutiny, both in our yeast model and in mammalian cells, which discriminates oncogenic and SHORT disease-associated mutations in PIK3R1.

Materials and methods

Strains, culture media, and growth conditions

All agar growth assays were performed with the S. cerevisiae YPH499 strain (MATa ade2-101 trp1-63 leu2-1 ura3-52 his3-A200 lys2-801). Growth conditions as well as serial dilution spot growth assays were described previously [20]. Halo growth assays were performed on the strain Y07202 (MATα; his3Δ1; leu2Δ0; met15Δ0; ura3Δ0; YDR007w::kanMX4) by using the 15e compound (PI3Kα inhibitor II Echelon®) as described previously [51].

Plasmid construction and transformations

Transformation of E. coli and yeast and other basic molecular biology methods were carried out using standard methods. Plasmids pYES2 and pYES3/CT (Invitrogen), pYES2–GFP–Akt1, pYES2–GFP–Akt1 (K179M), pYES2–PTEN, or pYES2–PTEN (C124S), YCpLG, YCpLG–p110α–CAAX, YCpLG–p110α (K802R)–CAAX, YCpLG–p110α, YCpLG–p110α (H1047R), YCpLG–p110α (E545K), YCpLG–p110β, and YCpLG–p110β–CAAX were already described [20,21]. YCpLG–Myr–p110α, YCpLG–MM–p110α, and YCpLG–FLAG–p110α were generated by PCR amplification of the first 1900 PIK3CA nucleotides from plasmids RCAS–Myr–p110α, RCAS–MM–p110α, and RCAS–FLAG–p110α [35] with primers containing BamHI/XbaI sites at 5’ tails and then subcloned into plasmid YCpLG–p110α [21]. Plasmids YCpLG–p110α (C2/4KA)–CAAX (K410A/R412A/K413A/K416A), YCpLG–p110α (C2/4KA)–H1047R, YCpLG–p110α (C2/4KA), YCpLG–p110α (K227E)–CAAX, YCpLG–p110β (K230E)–CAAX, YCpLG–p110α (K227E)–H1047R, p110α (K227E), and YCpLG–Myr–p110α (E545K) were generated by introducing the corresponding mutations on the aforementioned plasmids as templates using site-directed mutagenesis with Turbo Pfu DNA polymerase (Stratagene) and subsequent digestion with DpnI according to the QuikChange™ YCpLG–p110α (Δ1–11) YCpLG–p110α (Δ1–107)–CAAX YCpLG–p110β (Δ1–117) (Stratagene) recommendations.

Plasmids YCpLG–p110β, YCpLG–p110β–CAAX, YCpLG–p110β, YCpLG–p110δ–CAAX, YCpLG–p110α (Δ1–186), YCpLG–p110α (Δ1–186)–CAAX, YCpLG–p110α (Δ1–154)–CAAX, YCpLG–p110α (Δ1–107), YCpLG–p110α–CAAX YCpLG–p110β (Δ1–190), YCpLG–p110β (Δ1–190–CAAX), YCpLG–p110β (Δ1–117), and YCpLG–p110β (Δ1–117–CAAX) (all with an N-terminal myc-tag) were constructed by subcloning into the XbaI/Sall (p110γ, p110δ, and p110β truncation plasmids) or BamHI/Sall (p110α truncation plasmids) YCpLG linker sites the appropriate cDNAs, obtained from the corresponding pRK5 plasmids. The pRK5–Myc–p110 catalytic subunit and pRK5–Myc–p110 truncation plasmids will be described elsewhere, and were generated by cloning into pRK5 or pRK5–Myc the appropriate cDNAs, amplified by PCR using specific oligonucleotides and the corresponding plasmid templates: pCMVSPORT6 p110δ (mouse sequence) or pCMVSPORT6 p110y (human sequence) (both from Mammalian Gene Collection, GE Dharmacon, Lafayette, CO, USA), or YCpLG–p110α or YCpLG–p110β (wt and –CAAX; containing an N-terminal myc-tag) [21]. Plasmids pYES3–p85α, pYES3–p85α–CAAX, pYES3–p65α, pYES3–p65α–CAAX, pYES3–p55α, pYES3–p55α, pYES3–p85β, pYES3–p65β, pYES3–p55γ, and pYES3–p101 (all with an N-terminal HA epitope) were constructed by subcloning into the EcoRI/XhoI pYES3 linker sites the appropriate cDNAs with EcoRI/Sall flanking sites, obtained from the corresponding pRK5 plasmids. The pRK5–HA–PI3K-regulatory subunit plasmids will be described elsewhere, and were generated by cloning into pRK5 the appropriate cDNAs, amplified by PCR using specific oligonucleotides and the following plasmid templates: pCG–HA–p85α (mouse sequence; provided by A.C. Carrera, Centro Nacional de Biotecnología, Madrid, Spain), or pOTB7–p85β (human sequence), pCMVSPORT6–p55α (mouse sequence), pCMVSPORT6–p55γ (human sequence), and pCMVSPORT6–p101 (human sequence) (all from Mammalian Gene Collection, GE Dharmacon, Lafayette, CO, USA). Site-directed mutagenesis with the QuikChange™ kit on pYES3–p85α–CAAX was performed in order to obtain the different p85α mutations. All the oligonucleotide sequences used in the present study are available upon request. When analyzing the sequences to verify the point mutations, we observed that the pCG–HA–p85α template used corresponded to the deposited sequence GenBank AAA39886.1, which bears a
missense mutation as compared with the canonical NM_001077495.2 entry, involving a change of Glu\(^{510}\) to glycine (E510G). To verify that the presence of this amino acid change did not affect the validity of our results, we changed this residue back to glutamic acid by site-directed mutagenesis in our yeast expression vectors for HA–p65x and HA–p85x (both with and without the -CAAX signal) and tested them for their influence on yeast growth in co-expression with different p110 constructs used in the present study. The results obtained were totally unaffected by the E510G substitution in any case (results not shown).

Immunoblots
Western blotting assays were carried out by standard techniques. Anti-G6PDH antibody (Sigma; 1:50000 dilution) was used as loading control. Monoclonal anti-HA antibodies (Clone 12CA5, Roche; 1:1000) were used as primary antibodies to detect the expression of the HA-tagged regulatory PI3K subunits.

Acknowledgments
We thank P.K. Vogt, A.C. Carrera, and the U.K. Medical Research Council geneservice (Mammalian Gene Collection) for providing plasmids; A. Andrés-Pons for the initial cloning of PI3K cDNAs; and I. Roglá for technical assistance. We are also grateful to the Unidad de Genómica y Proteómica UCM for sequencing.

Funding
This work was supported by Ministerio de Ciencia e Innovación (Spain and Fondo Europeo de Desarrollo Regional [grant number SAF2009-10226]; Ministerio de Economía y Competitividad (Spain) [grant number SAF2013-48812-R]; Ministerio de Economía y Competitividad (Spain) [grant numbers BIO2010-22369-C02-01 and BIO2013-44112-P]; Comunidad Autónoma de Madrid (Spain) [grant number S2011/BMD-2414]; and Bilbao Bizkaia Kutxa (BBK) (Spain) to S.L.

Competing interests
The authors declare that there are no competing interests associated with the manuscript.

Author contribution
R.P., M.M., and V.J.C. designed the study and wrote the paper. T.F.A. substantially contributed to the writing. M.D.O., T.F.A., S.L., and I.R.E. designed and constructed vectors for expression of PI3K isoforms. M.D.O. and T.F.A. performed all yeast phenotypic analyses and associated experiments, and participated in key points of the design of the study. All authors analyzed the results and approved the final version of the manuscript.

Abbreviations
ABD, adaptor-binding domain; cSH2, C-terminal SH2; GAP, GTPase-activating protein; IRS-1, insulin receptor substrate-1; iSH2, intermediate SH2; mTOR, mammalian target of rapamycin; nSH2, N-terminal SH2; PDK, phosphoinositide-dependent kinase; PI3K, phosphatidylinositol 3-kinase; PTEN, phosphatase and tensin homolog deleted on chromosome ten; RBD, Ras-binding domain; RTK, receptor tyrosine kinase; SHORT, short stature, hyperextensibility of joints or inguinal hernia, ocular depression, rieger anomaly, and teething delay; TCGA, The Cancer Genome Atlas; WT, wild type.

References
1 Cheung, M. and Testa, J. R. (2013) Diverse mechanisms of AKT pathway activation in human malignancy. Curr. Cancer Drug Targets 13, 234–244
2 Vogt, P.K., Hart, J.R., Gimpl, M., Jiang, H., Kang, S., Bader, A.G. et al. (2010) Phosphatidylinositol 3-kinase: the oncoprotein. Curr. Top. Microbiol. Immunol. 347, 79–104
3 Dibble, C.C. and Cantley, L.C. (2015) Regulation of mTOR1 by PI3K signaling. Trends Cell Biol. 25, 545–555
4 Martini, M., De Santis, M.C., Braccini, L., Gullini, F. and Hirsch, E. (2014) PI3K/AKT signaling pathway and cancer: an updated review. Ann. Med. 46, 372–383
5 Milella, M., Falcone, I., Conciatori, F., Cesta Incani, U., Del Curatolo, A., Inzerilli, N. et al. (2015) PTEN: multiple functions in human malignant tumors. Front. Oncol. 5, 24
6 Pulido, R. (2015) PTEN: a Yin-yang master regulator protein in health and disease. Methods 77–78, 3–10
7 Worby, C.A. and Dixon, J.E. (2014) PTEN. Annu. Rev. Biochem. 83, 641–669
8 Song, M.S., Salmena, L. and Pandolfi, P.P. (2012) The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol. 13, 283–296
9 Urlick, M.E., Rudd, M.L., Godwin, A.K., Sgroi, D., Merino, M. and Bell, D.W. (2011) PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res. 71, 4061–4067
10 Samuels, Y. and Waldman, T. (2010) Oncogenic mutations of PK3CA in human cancers. Curr. Top. Microbiol. Immunol. 347, 21–41
11 Rudd, M.L., Price, J.C., Fogores, S., Godwin, A.K., Sgroi, D.C., Merino, M.J. et al. (2011) A unique spectrum of somatic PK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin. Cancer Res. 17, 1331–1340

© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution Licence 4.0 (CC BY).
12 Jaiswal, B.S., Janakiraman, V., Kijavin, N.M., Chaudhuri, S., Stern, H.M., Wang, W. et al. (2009) Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell 16, 463–474
13 Liu, S., Knapp, S. and Ahmad, A.A. (2014) The structural basis of PI3K cancer mutations: from mechanism to therapy. Cancer Res. 74, 641–646
14 Jiménez, C., Jones, D.R., Rodríguez-Viciana, P., González-García, A., Leonardo, E., Wennstrom, S. et al. (1998) Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase. EMBO J. 17, 743–753
15 Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S. et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554
16 Huang, C.H., Mandelker, D., Schmidt-Kittler, O., Samuels, Y., Velculescu, V.E., Kinzler, K.W. et al. (2007) The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PIK3CA mutations. Science 318, 1744–1748
17 Kandoth, C., Schultz, N., Cheriack, A.D., Akbani, R., Liu, Y., Shen, H. et al. (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497, 67–73
18 Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490, 61–70
19 Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061–1068
20 Rodríguez-Escudero, I., Roelants, F.M., Thorner, J., Nombela, C., Molina, M. and Cid, V.J. (2005) Reconstitution of the mammalian PI3K/PTEN/Akt pathway in yeast. Biochem. J. 390, 613–623
21 Andrés-Pons, A., Rodríguez-Escudero, I., Gil, A., Blanco, A., Vega, A., Molina, M. et al. (2007) In vivo functional analysis of the counterbalance of hyperactive phosphatidylinositol 3-kinase p110 catalytic oncoproteins by the tumor suppressor PTEN. Cancer Res. 67, 9731–9739
22 Cid, V.J., Rodríguez-Escudero, I., Andrés-Pons, A., Romá-Mateo, C., Gil, A., den Hertog, J. et al. (2008) Assessment of PTEN tumor suppressor activity in nonmammalian models: the year of the yeast. Oncogene 27, 5431–5442
23 Gil, A., Rodríguez-Escudero, I., Stumpf, M., Molina, M., Cid, V.J. and Pulido, R. (2015) A functional dissection of PTEN N-terminus: implications in PTEN subcellular targeting and tumor suppressor activity. PLoS ONE 10, e0119287
24 Rodríguez-Escudero, I., Fernández-Acero, T., Bravo, I., Leslie, N.R., Pulido, R., Molina, M. et al. (2015) Yeast-based methods to assess PTEN phosphoinositide phosphatase activity in vivo. Methods 77–78, 172–179
25 Rodríguez-Escudero, I., Oliver, M.D., Andrés-Pons, A., Molina, M., Cid, V.J. and Pulido, R. (2011) A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes. Hum. Mol. Genet. 20, 4132–4142
26 Chudasama, K.K., Winnay, J., Johansson, S., Claudi, T., Konig, R., Haldorsen, I., et al. (2013) SHORT syndrome with partial lipodystrophy due to impaired phosphatidylinositol 3 kinase signaling. Am. J. Hum. Genet. 93, 150–157
27 Dyment, D.A., Smith, A.C., Alcantara, D., Schwartzentruber, J.A., Basel-Vanagaite, L., Curry, C.J. et al. (2013) Mutations in PIK3R1 cause SHORT syndrome. Am. J. Hum. Genet. 93, 158–166
28 Thauvin-Robinet, C., Auclair, M., Duplomb, L., Caron-Debarle, M., Avila, M., St-Onge, J. et al. (2013) PIK3R1 mutations cause syndromic insulin resistance with lipodystrophy. Am. J. Hum. Genet. 93, 141–149
29 Rodríguez-Escudero, I., Andrés-Pons, A., Pulido, R., Molina, M. and Cid, V.J. (2009) Phosphatidylinositol 3-kinase-dependent activation of mammalian protein kinase B/Akt in Saccharomyces cerevisiae, an in vivo model for the functional study of Akt mutations. J. Biol. Chem. 284, 13373–13383
30 Huang, C.H., Mandelker, D., Gabelli, S.B. and Amzel, L.M. (2008) Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha. Cell Cycle 7, 1151–1156
31 Kodaki, T., Woscholski, R., Hallberg, B., Rodríguez-Viciana, P., Downward, J. and Parker, P.J. (1994) The activation of phosphatidylinositol 3-kinase by Ras. Curr. Biol. 4, 798–806
32 Powers, S., Kataoka, T., Fasano, O., Goldfarb, M., Strathern, J., Broach, J. et al. (1984) Genes in S. cerevisiae encoding proteins with domains homologous to the mammalian ras proteins. Cell 36, 607–612
33 Rodríguez-Viciana, P., Warne, P.H., Vanhaesebroeck, B., Waterfield, M.D. and Downward, J. (1996) Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation. EMBO J. 15, 2442–2451
34 Zhao, J.J., Liu, Z., Wang, L., Shin, E., Loda, M.F. and Roberts, T.M. (2005) The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 102, 18443–18448
35 Sun, M., Hart, J.R., Hillmann, P., Gymnopoulou, M. and Vogt, P.K. (2011) Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110alpha/phosphoinositide-3-kinase. Cell Cycle 10, 3731–3739
36 Miled, N., Yan, Y., Hon, W.C., Perisic, O., Zvelebil, M., Inbar, Y. et al. (2007) Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 317, 239–242
37 Hofmann, B.T. and Jucker, M. (2012) Activation of PI3K/Akt signaling by n-terminal SH2 domain mutants of the p85alpha regulatory subunit of PI3K is enhanced by deletion of its c-terminal SH2 domain. Cell. 24, 1950–1954
38 Wu, H., Shekar, S.C., Flinn, R.J., El-Sibai, M., Jaiswal, B.S., Sen, K.I. et al. (2009) Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110alpha and are disrupted in oncogenic p85 mutants. Proc. Natl. Acad. Sci. U.S.A. 106, 20258–20263
39 Innes, A.M. and Dyment, D.A. (1993) SHORT syndrome. In GeneReviews(R) (Pagon, R.A., Adam, M.P., Ardinger, H.H., Wallace, S.E., Amemiya, A., Bean, L.J.H., Bird, T.D., Fong, C.T., Mefford, H.C., Smith, R.J.H. and Stephens, K., eds), University of Washington, WA, Seattle
40 Vadas, O., Burke, J.E., Zhang, X., Berndt, A. and Williams, R.L. (2011) Structural basis for activation and inhibition of class I phosphoinositide 3-kinases. Sci. Signal. 4, re2
41 Fu, Z., Aronoff-Spencer, E., Backer, J.M. and Gerfen, G.J. (2003) The structure of the inter-SH2 domain of class IA phosphoinositide 3-kinase determined by site-directed spin labeling EPR and homology modeling. Proc. Natl. Acad. Sci. U.S.A. 100, 3275–3280
42 Ikenoue, T., Kanai, F., Okita, Y., Obata, T., Tanaka, Y., Imamura, J. et al. (2005) Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res. 65, 4562–4567

© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
43 Sun, M., Hillmann, P., Hofmann, B.T., Hart, J.R. and Vogt, P.K. (2010) Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha. Proc. Natl. Acad. Sci. U.S.A. 107, 15547–15552
44 Mandelker, D., Gabelli, S.B., Schmidt-Kittler, O., Zhu, J., Cheong, I., Huang, C.H. et al. (2009) A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane. Proc. Natl. Acad. Sci. U.S.A. 106, 16996–17001
45 Hon, W.C., Berndt, A. and Williams, R.L. (2012) Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases. Oncogene 31, 3655–3666
46 Zhao, L. and Vogt, P.K. (2008) Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc. Natl. Acad. Sci. U.S.A. 105, 2652–2657
47 Carson, J.D., Van Aller, G., Lehr, R., Sinnamon, R.H., Kirkpatrick, R.B., Auger, K.R. et al. (2008) Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase. Biochem. J. 409, 519–524
48 Gekka, P., Evangelidis, T., Pavlaki, M., Lazani, V., Christoforidis, S., Agianian, B. et al. (2014) Investigating the structure and dynamics of the PIK3CA wild-type and H1047R oncogenic mutant. PLoS Comput. Biol. 10, e1003895
49 Burke, J.E., Perisic, O., Masson, G.R., Vadas, O. and Williams, R.L. (2012) Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110alpha (PIK3CA). Proc. Natl. Acad. Sci. U.S.A. 109, 15259–15264
50 Winnay, J.N., Solheim, M.H., Dirice, E., Sakaguchi, M., Noh, H.L., Kang, H.J. et al. (2016) PI3-kinase mutation linked to insulin and growth factor resistance in vivo. J. Clin. Invest. 126, 1401–1412
51 Fernández-Acero, T., Rodríguez-Escudero, I., Vicente, F., Monteiro, M.C., Tormo, J.R., Cantizani, J. et al. (2012) A yeast-based in vivo bioassay to screen for class I phosphatidylinositol 3-kinase specific inhibitors. J. Biomol. Screen. 17, 1018–1029
52 Forbes, S.A., Beare, D., Gunasekaran, P., Leung, K., Bindal, N., Boutselakis, H. et al. (2015) COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Res. 43, D805–D811